A mechanism for circumventing apoptosis prevalent in many cancer cells is the overexpression of antiapoptotic BCL-2 family members. Upregulated expression of BCL-2 may be required to permit ongoing death signaling without a cellular response. Therefore, antagonizing BCL-2 function may cause death in many cancer cells. The selection for expression of BCL-2 or other antiapoptotic proteins during oncogenesis may derive from these proteins' ability to bind and sequester proapoptotic BH3-only proteins. This situation may be advantageous from a therapeutic viewpoint because cancer cells may be distinguished from normal cells by being primed with death signals. There are several strategies currently under investigation that may lead to improved treatment of many cancers by taking advantage of these differences. © 2007 Springer Science + Business Media B.V.
CITATION STYLE
Moore, V. D. G., & Letai, A. (2008). Rational design of therapeutics targeting the BCL-2 family: Are some cancer cells primed for death but waiting for a final push? Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-1-4020-6554-5_8
Mendeley helps you to discover research relevant for your work.